These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7587121)

  • 1. Genes coding for tumor-specific rejection antigens.
    Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora JP; De Backer O
    Cold Spring Harb Symp Quant Biol; 1994; 59():617-22. PubMed ID: 7587121
    [No Abstract]   [Full Text] [Related]  

  • 2. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 3. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes.
    Coulie P; Weynants P; Muller C; Lehmann F; Herman J; Baurain JF; Boon T
    Ann N Y Acad Sci; 1993 Aug; 690():113-9. PubMed ID: 8368730
    [No Abstract]   [Full Text] [Related]  

  • 4. Protein tumor antigens.
    Srivastava PK
    Curr Opin Immunol; 1991 Oct; 3(5):654-8. PubMed ID: 1755984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
    Van den Eynde B; Peeters O; De Backer O; Gaugler B; Lucas S; Boon T
    J Exp Med; 1995 Sep; 182(3):689-98. PubMed ID: 7544395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
    Uyttenhove C; Maryanski J; Boon T
    J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human tumor rejection antigens MAGE.
    Itoh K; Hayashi A; Nakao M; Hoshino T; Seki N; Shichijo S
    J Biochem; 1996 Mar; 119(3):385-90. PubMed ID: 8830028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
    Boon T
    Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
    [No Abstract]   [Full Text] [Related]  

  • 9. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
    Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
    Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.
    De Plaen E; Lurquin C; Van Pel A; Mariamé B; Szikora JP; Wölfel T; Sibille C; Chomez P; Boon T
    Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2274-8. PubMed ID: 3127830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of genes encoding T cell defined tum- antigens.
    Van Pel A; De Plaen E; Lurquin C; Van den Eynde B; Lethé B; Hainaut P; Lemoine C; Boon T
    Princess Takamatsu Symp; 1988; 19():255-63. PubMed ID: 3151988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
    Van den Eynde B; Lethé B; Van Pel A; De Plaen E; Boon T
    J Exp Med; 1991 Jun; 173(6):1373-84. PubMed ID: 1903428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 T cell help for innate antitumor immunity.
    Shanker A; Verdeil G; Buferne M; Inderberg-Suso EM; Puthier D; Joly F; Nguyen C; Leserman L; Auphan-Anezin N; Schmitt-Verhulst AM
    J Immunol; 2007 Nov; 179(10):6651-62. PubMed ID: 17982055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teaching the immune system to fight cancer.
    Boon T
    Sci Am; 1993 Mar; 268(3):82-9. PubMed ID: 8316825
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
    Kacha AK; Fallarino F; Markiewicz MA; Gajewski TF
    J Immunol; 2000 Dec; 165(11):6024-8. PubMed ID: 11086033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
    Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
    J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining tumor antigens: mRNA, protein or cytotoxicity?
    Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
    Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
    [No Abstract]   [Full Text] [Related]  

  • 18. [Melanoma antigen genes(MAGE) and malignant tumors].
    Xu JZ; Lin S
    Ai Zheng; 2003 Sep; 22(9):1001-4. PubMed ID: 12969539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
    Colmenero P; Liljeström P; Jondal M
    Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53.
    Ciernik IF; Berzofsky J; Carbone DP
    Hybridoma; 1995 Apr; 14(2):139-42. PubMed ID: 7590770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.